Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer

By Jerusalem Guy   Fasolo Angelica   Dieras Veronique   Cardoso Fatima   Bergh Jonas   Vittori Luc   Zhang Yufen   Massacesi Cristian   Sahmoud Tarek   Gianni Luca  

Breast Cancer Research and Treatment, Vol. 125, Iss. 2, 2011-01 ,pp. : 447-455

Springer Publishing Company

Access to resources Recommend Favorite

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors

By Macaulay V. M.   Middleton M. R.   Protheroe A. S.   Tolcher A.   Dieras V.   Sessa C.   Bahleda R.   Blay J.-Y.   LoRusso P.   Mery-Mignard D.   Soria J.-C.  

Annals of Oncology, Vol. 24, Iss. 3, 2013-03 ,pp. : 784-791

Oxford University Press

Access to resources Recommend Favorite

Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer

By Albanell Joan  

The Women's Oncology Review, Vol. 4, Iss. 1, 2004-01 ,pp. : 43-44

Informa Healthcare

Access to resources Recommend Favorite

Oral Gossypol in the Treatment of Patients with Refractory Metastatic Breast Cancer: A Phase I/II Clinical Trial

By van Poznak C.  

Breast Cancer Research and Treatment, Vol. 66, Iss. 3, 2001-04 ,pp. : 239-248

Springer Publishing Company

Access to resources Recommend Favorite

Phase I trial of liposomal doxorubicin and ZD1839 in patients with refractory gynecological malignancies or metastatic breast cancer

By Campos Susana   Berlin Suzanne   Parker Leroy   Chen Wendy   Bunnell Craig   Atkinson Tina   Lee Julie   Matulonis Ursula   Hirsch Michelle   Harris Lyndsay   Krasner Carolyn  

International Journal of Clinical Oncology, Vol. 15, Iss. 4, 2010-08 ,pp. : 390-398

Springer Publishing Company

Access to resources Recommend Favorite